Federal officials, medical experts and drugmakers are calling for faster approval of new antibiotics to deal with outbreaks of drug-resistant bacteria. Long trials should give way to direct and faster testing in very ill patients as the need for new antibiotics is critical, according to supporters of an overhaul. The Infectious Disease Society of America proposed a special label and limits for new antibiotics approved through quicker testing, but critics argue that short trials might not be able to adequately assess effectiveness and safety.

Related Summaries